Intellia Therapeutics (NTLA) Net Margin (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Net Margin data on file, last reported at 1277.02% in Q1 2026.

• On a quarterly basis, Net Margin rose 25623.0% year-over-year to 1277.02% in Q1 2026; TTM through Mar 2026 was 945.8%, a 51960.0% increase from a year earlier, with the FY2025 full-year figure at 1960.12%, up 23361.0% from the prior year.
• Net Margin for Q1 2026 stood at 1277.02%, down from 400.94% in the prior quarter.
• Over the last five years, Net Margin for NTLA reached as high as 8521.39% in Q4 2023 and fell as low as 3097.89% in Q1 2022.
• Historically, Net Margin has averaged 774.62% across 5 years, with a median of 1319.11% in 2023.
• Across the five-year window, Net Margin surged 1447721 bps in 2022 and tumbled 950394 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 799.79% in 2022, then jumped by 1165 bps to 8521.39% in 2023, then tumbled by 112 bps to 982.55% in 2024, then surged by 59 bps to 400.94% in 2025, then plunged by 219 bps to 1277.02% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 1277.02% in Q1 2026, 400.94% in Q4 2025, and 1613.8% in Q3 2025.